Is it clear when upadacitinib will be launched in China?

Upadacitinib is a reversible, orally selectiveJAK1 inhibitor that plays an important role in multiple types of inflammatory conditions,including rheumatoid arthritis, active spondyloarthritis and moderate to severe psoriatic arthritis. These patients often have an inadequate response to or are in an intolerant active phase to one or moreTNF blockers. Upadatinib’s original drug has not yet been launched in China, but it is being gradually approved. The price of upadatinib’s original drug for overseas marketing is around 27,000 yuan (The price may fluctuate due to exchange rates).